Consistent with this, doxorubicin treatment caused a significant increase in cytoplasmic DNA levels in STS cells (Figure 1B), resulting in the upregulation of STING at the protein level and increased expression of type I IFN signature genes, including Ccl5, Cxcl10, and Ifnb1 in mouse sarcoma cells, and CCL5, CXCL10, IFNB1 in human sarcoma cells (Figure 1C, and Supplementary Figures 1B, C). The gene discussed is IFNB1; the disease is telomere syndrome.